Medicines for rare diseases

    Discover
    ORPHELIA Pharma

    Development of essential medicines in the field of rare and pediatric diseases.

    Read more

    Discover
    Products & Projects

    Focus on deadly epileptic childhood syndromes and refractory and relapsed pediatric cancers.

    therapeutics areas
    Our products

    Latest news

    Visit our news flow to access our press release and latest news.

    6 July 2022

    OCTALFA announces the inclusion of the first patient in the French Early Access Program granted to its subsidiary ORPHELIA Pharma for the use of KIMOZO® 40 mg/ml (temozolomide oral suspension) in the treatment of relapsed or refractory neuroblastoma

    Read More
    9 June 2022

    ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children

    Read More
    31 May 2022

    ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide)

    Read More